Boston Scientific reports 1.50 percent Q3 growth. Boston Scientific stock trades at EUR 37.61

Boston Scientific reported third-quarter sales growth of 1.50 percent on October 28, 2026, while its updated full-year outlook points to a slower finish. The company said the quarter and forward view reflected the effects of an August cybersecurity incident, according to Boston Scientific Corporation.

Growth slowed across the portfolio

Net sales reached USD 5.138 billion in the third quarter ended September 30, 2026. GAAP net income attributable to common stockholders was USD 582 million, down from USD 755 million in the year-earlier quarter, while adjusted earnings per share was USD 0.73 versus USD 0.75.

The segment mix was uneven. Cardiovascular sales grew 1.90 percent, while MedSurg sales increased 0.70 percent. The company also reported new product clearances and a collaboration with Heartflow to advance CT-guided planning for coronary procedures.

What does the revised outlook mean?

Boston Scientific now guides to 4.25 percent reported sales growth and 3.75 percent organic growth for full-year 2026. Fourth-quarter sales are expected to decline between 3.00 percent and 1.00 percent from the prior-year period, with adjusted earnings per share guided to USD 0.77 to USD 0.79.

The figures make the cybersecurity disruption a central issue for the near-term outlook, while the company continues to point to its product pipeline and long-term strategy. The revised forecast gives investors a clearer measure of the recovery hurdle entering the final quarter.

Stock price in Berlin trading

Boston Scientific stock was trading intraday at EUR 37.61 at Lang & Schwarz on October 29, 2026 at 3:36 p.m. Berlin time. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.

Market context: Market report S&P 500.

More news and analyses on Boston Scientific stock